Thromboelastography: Potential bedside tool to assess the effects of antiplatelet therapy?

Platelets

Volumn 17, Issue 6, 2006, Pages 385-392

  Swallow, R A ^a   Agarwala, R A ^b   Dawkins, K D ^a   Curzen, N P ^a,b  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Antiplatelet therapy; Thromboelastography

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; CLOPIDOGREL; FIBRIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MEDICAL PRACTICE; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOELASTOGRAPHY;

ADULT; ASPIRIN; BLOOD PLATELETS; FEMALE; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POINT-OF-CARE SYSTEMS; THROMBELASTOGRAPHY; THROMBOSIS; TICLOPIDINE; TIME FACTORS;

EID: 33748779290     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.1080/09537100600757521     Document Type: Article

References (35)

1. Antithrombotics Trialists' Collaboration. Prevention of death, myocardial infarction and stroke by antiplatelet therapy in high-risk patients. Br Med J 2002;324:71-86.
2. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Barrera-Ramirez C, Sabate M, Hernandez R, Moreno R, Escaned J, Alfonso F, Banuelos C, Costa MA, Bass TA, Macaya C. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res. 2005;115(1-2):101-108.
3. Michelson AD. Platelet function testing in cardiovascular disease. Circulation 2004;1110:e489-93.
4. Mallett SV, Cox DJ. Thrombelastography. Br J Anaesthesia 1992;69:307-313.
5. Salooja N, Perry D. Thrombelastography. Blood Coagul Fibrinolysis 2001;12:327-337.
6. Kang YG, Martin DJ, Marquez J, Lewis JH, Bontempo FA, Shaw BW, Starzl TE, Winter PM. Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anaesthesia Analgesia 1985;64:888-896.
7. Cammerer U, Dietrich W, Rampf T, Braun SL, Richter JA. The predictive value of modified computerized thrombelastography and platelet function analysis for postoperative blood loss in routine cardiac surgery. Anaesthesia Analgesia 2003;96(1):51-57.
8. Kettner SC, Panzer OP, Kozek SA, Seibt FA, Stoiser B, Kofler J, Locker GJ, Zimpfer M. Use of abciximab-modified thrombelastography in patients undergoing cardiac surgery. Anaesthesia Analgesia 1999;89(3):580-584.
9. Samama CM. Thrombelastography: the next step. Anaesthesia Analgesia 2001;92:563-564.
10. Christiaens L, Macchi L, Herpin D, Coisne D, Duplantier C, Allal J, Mauco G, Brizard A. Resistance to aspirin in vitro at rest and during exercise inpatients with angiographically proven coronary artery disease. Thromb Res 2002;108 (2-3):115-119.
11. Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin non-responesiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2002;108(1):37-42.
12. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41(6):961-965.
13. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105(14):1650-1655.
14. Grundmann K, Jashonek K, Kleine B, Dichgans J, Topka H. Aspirin non-responder status in patients with recurrent cerebrovascular ischemic attacks. J Neurol 2003;250(1):63-66.
15. Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable anginas pectoris scheduled for elective coronary stent placement. Throb Haemost 2003;89 (5):783-787.
16. Jaremo P, Lindahl TL, Fransson SG, Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002;252(3):233-238.
17. Colwell JA, Nair RM, Halushka PV, Rogers C, Whetsell A, Sagel J. Platelet adhesion and aggregation in diabetes mellitus. Metabolism 1979;28(4 Suppl 1):394-400.
18. Tamminen M, Lassila R, Westerbacka J, Vehkavaara S, Yki-Jarvine M. Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects. Int J Obes Relat Metab Disord 2003;27(8):907-911.
19. Gurbel P, Bliden K, Guyer K, Cho P, Zaman K, Kreutz R, Bassi A, Tantry U. Platelet reactivity in patients and recurrent events post-stenting. Results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005;46:1820-1826.
20. Tantry U, Bliden K, Gurbel P. Overestimation of platelet aspirin resistance detection by thromboleastograph platelet mapping and validation by conventional aggreagometry using arachidonic acid stimulation. J Am Coll Cardiol 2005;46:170-179.
21. Carroll RC, Craft RM, Chavez JJ, Snider CC, Bresee SJ, Cohen E. A Thrombelastograph whole blood assay for clinical monitoring of NSAID-insensitive transcellular platelet activation by arachidonic acid. J Lab Clin Med 2005;146(1):30-35.
22. Craft RM, Chavez JJ, Snider CC, Muenchen RA, Carroll RC. Comparison of modified Thrombelastograph and Plateletworks whole blood assays to optical platelet aggregation for monitoring reversal of clopidogrel inhibition in elective surgery patients. J Lab Clin Med 2005;145(6):309-315.
23. Practical implementation of the guidelines for unstable angina/non ST elevation MI in the emergency department. AHA Scientific Statement. Circulation 2005;111:2699-2710.
24. CURE Steering Committee. Effects of Clopidogrel in addition in patients with acute coronary syndromes without ST-segment elevation. New Engl J Med 2001;345:494-502.
25. Guidelines for percutaneous coronary interventions. Taskforce on PCI for the European Society of Cardiology. Eur Heart J 2005;26:804-847.
26. Bertand ME, Rupprecht HJ, Urban P et al. Double-blind study of the safety of clopidogrel with or without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. The clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000;102:624-629.
27. Steinhubl SR, Berger PB, Mann JT. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomised controlled trial. J Am Med Assoc 2002;288:2411-2420.
28. Kandzari DE, Berger PB, Kastrati A et al. Influence of treatment duration with a 600mg dose of clopidogrel before percutaneous coronary revascularisation. J Am Coll Cardiol 2004;44:2133-2136.
29. Pappas JM, Westengard JC, Bull BS. Population Variability in the effect of aspirin on platelet function. Implications for clinical trials and therapy. Arch Pathol Lab Med 1994;118:801-804.
30. Gum PA, Kottke-Marchant K, Welsh P, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41(6):961-965.
31. Jaremo P, Lindahl TL, Fransson SG, Richter A. Individual variations of platelet inhibition after loading doses of Clopidogrel. J Intern Med 2003;252:233-238.
32. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pre-treatment platelet activity. Circulation 2003;107(23):2908-2914.
33. Wenaweser P, Dorffler-Melly J, Imboden K et al. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 2005;45:1748-1752.
34. Lev E, Bray P, Delao T, Grenada J, Kleiman N. Aspirin and clopidogrel drug response in patients undergoing PCI: a role for dual drug resistance?. J Am Coll Cardiol 2005;45(3 suppl A):86A.
35. Greilich PE, Carr ME, Cooley MV. Dose dependent effects of c7E3 Fab on modified Thrombelastograph analysis in healthy volunteers. Anesth Analg 1998;86:S64.